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The p38alpha mitogen-activated protein kinase
limits the CNS proinflammatory cytokine response
to systemic lipopolysaccharide, potentially
through an IL-10 dependent mechanism
Adam D Bachstetter1, Bin Xing1,3 and Linda J Van Eldik1,2*
Abstract
Background: The p38α mitogen-activated protein kinase (MAPK) is a well-characterized intracellular kinase involved
in the overproduction of proinflammatory cytokines from glia. As such, p38α appears to be a promising therapeutic
target for neurodegenerative diseases associated with neuroinflammation. However, the in vivo role of p38α in cytokine
production in the CNS is poorly defined, and prior work suggests that p38α may be affecting a yet to be identified
negative feedback mechanism that limits the acute, injury-induced proinflammatory cytokine surge in the CNS.
Methods: To attempt to define this negative feedback mechanism, we used two in vitro and two in vivo models of
neuroinflammation in a mouse where p38α is deficient in cells of the myeloid lineage.
Results: We found that p38α in myeloid cells has an important role in limiting amplitude of the acute proinflammatory
cytokine response to a systemic inflammatory challenge. Moreover, we identified IL-10 as a potential negative feedback
mechanism regulated by p38α.
Conclusions: Our data suggest that p38α regulates a proper balance between the pro- and anti-inflammatory cytokine
responses to systemic inflammation, and that if circulating IL-10 levels are not elevated to counter-balance
the increased systemic proinflammatory responses, the spread of the inflammatory response from the periphery
to the CNS is exaggerated.
Keywords: cytokines, glia, interleukin, neuroinflammation, signal transduction, tumor necrosis factor alpha
Introduction
Inflammation is a complex response that requires tight
regulatory control of its initiation and resolution. In the
central nervous system (CNS), neuroinflammation has
gained increasing support as a contributing mechanism
in a number of neurodegenerative diseases [1,2], includ-
ing Alzheimer’s disease (AD) [3] and Parkinson’s disease
[4], as well as acute neurodegenerative conditions such as
traumatic brain injury (TBI) [5], spinal cord injury [6] and
stroke [7]. As one aspect of neuroinflammation, proinflam-
matory cytokines have been linked to tissue injury and
disease processes [8,9]. For example, overproduction of IL-
1β by activated microglia can induce pathological tau
phosphorylation and a decline in synaptophysin levels in
neurons [10,11]. Cytokine production is regulated at mul-
tiple levels; however, one intracellular mechanism involved
in upregulated cytokine production is the p38 mitogen-
activated protein kinase (MAPK). The p38 MAPK family
consists of at least four isoforms (p38α,β,δ,γ), which are
encoded by separate genes, expressed in different tissues
and cell types, and are often functionally distinct [12].
Mechanistically, the p38 MAPKs phosphorylate protein sub-
strates that are downstream targets involved in the regula-
tion of proinflammatory cytokine gene expression through
effects on transcription and translation (for review see: [12]).
Since the discovery of the pyridinyl imidazole class of
small molecule anti-inflammatory compounds that inhibit
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the activity of p38 (commonly known as ‘SB’ compounds)
[13], extensive resources have been allocated to the
development and refinement of p38 inhibitors for the
treatment of peripheral inflammatory diseases [14,15].
A few studies have used small molecule p38 inhibitors
in vivo to demonstrate that pharmacological inhibition
of p38α is neuroprotective in animal models of CNS
disorders, such as AD [16,17], global and focal ischemia
[18-21], neuropathic pain [22], and seizures [23]. However,
human clinical trial experience with p38α inhibitors has
yielded mixed results. Published data on the effects of p38
inhibition in cardiovascular disease, chronic obstructive
pulmonary disease, and neuropathic pain show encour-
aging results, whereas trials in rheumatoid arthritis and
Crohn’s disease show limited, if any, efficacy (for review
see: [24]). These results emphasize the importance of a
better understanding of the in vivo role of p38α in various
inflammatory diseases, especially neuroinflammatory dis-
orders of the CNS.
While p38α appears promising as a therapeutic target
for neurodegenerative diseases [17,25,26], more preclin-
ical work is necessary to determine the appropriate dis-
ease indications, therapeutic window, and potential side
effects of inhibiting the p38α pathway. For example,
in vitro studies have demonstrated that the p38α isoform
contributes to approximately 50% of the IL-1β and TNFα
produced by microglia in response to inflammatory stimuli
[27]. In contrast, following a diffuse TBI in mice with a
genetic knockdown of p38α in cells of the myeloid lineage
(p38αΔLysM-Cre KO mice), an enhanced CNS acute cytokine
surge (more IL-1β, IL-6, TNFα) was found at 6 hr post-
injury; however by 7 days post-injury, cytokine levels in the
p38αΔLysM-Cre KO mice were below that of the injured
wild-type (WT) mice [28]. These results suggest that p38α
may be affecting a yet to be identified negative feedback
mechanism that limits the acute cytokine surge occurring
during the first hours after an in vivo insult, which is not
evident in vitro. The goal of this project was to explore the
potential mechanism by which p38α could suppress the
acute proinflammatory cytokine response in the CNS. We
report here that the CNS proinflammatory response to sys-
temic lipopolysaccharide (LPS) administration is enhanced
in the p38αΔLysM-Cre KO mice compared to WT mice, and
that p38α is required by myeloid cells to produce IL-10
in response to LPS. Our results suggest that p38α has
a critical role in limiting the spread of the peripheral in-
flammatory response to the CNS through regulating the
production of the anti-inflammatory cytokine IL-10.
Materials and methods
Reagents
Lipopolysaccharides (LPS) from Salmonella enterica
serotype typhimurium (Sigma-Aldrich, St. Louis, MO,
USA: Cat. no. L6143-1MG; EU/MG of LPS is 600,000)
was prepared in sterile 0.9% sodium chloride that was
free of preservatives (Hospira, Inc., Lake Forest, IL: cat.
no. NDC 0409-4888-10). Sterile 0.9% sodium chloride
was used as the vehicle (veh) control in all experiments.
Animals
Experiments were conducted in accordance with the prin-
ciples of animal care and experimentation in the Guide
For the Care and Use of Laboratory Animals. The
Institutional Animal Care and Use Committee of the
University of Kentucky approved the use of animals in
this study (protocol #2010-0615). The p38αΔLysM-Cre KO
mice were generated as previously described [29]. The first
exon of the p38α gene (MAPK14) was flanked by two loxP
sites. The p38α floxed mice were maintained as homozy-
gotes: p38αfl/fl. To induce cell-specific deletion of p38α
MAPK in myeloid cells including macrophages and
microglia, the p38αfl/fl mice were crossed with mice that
contain Cre driven by the lysozyme promoter. The re-
stricted cell-type expression of the lysozyme promoter
[30,31] results in myeloid cell-specific deletion, as we have
previously validated [27,28,32]. The mice were back-
crossed to generate mice that were null for mouse WT
p38α, homozygous for floxed p38α, and hemizyogous for
LysM-Cre: p38αfl/fl;LysM-Cre. The p38αfl/fl were crossed
with the p38αfl/fl;LysM-Cre to generate litters where approxi-
mately 50% of the mice are microglia/macrophage condi-
tional p38α KO (p38αΔLysM-Cre KO) and approximately
50% are p38αfl/fl littermates (used as WT controls). All ex-
periments used both genders of mice at approximately a
50:50 ratio. Genotyping was performed by Transnetyx, Inc
(Cordova, TN, USA). On the basis of preliminary data and
prior published work [27], we find cytokine levels to be
consistently below or at the limit of detection in unstimu-
lated mice. Therefore, to reduce the total number of mice
needed for the experiments, the number of mice treated
with veh alone was kept to the minimum (n = 2 per group/
time point) necessary to confirm there was no elevated
basal cytokine response due to experimental manipulation
or other idiopathic cause.
Lipopolysaccharide administration
For intracerebroventricular (ICV) administration of LPS,
three to four month old male and female mice were
anesthetized with 5% isoflurane prior to stabilizing the
head using ear bars in a digital mouse stereotaxic frame
(Stoelting Co, Wood Dale, IL, USA). Anesthesia was
maintained with continuous inhalation of isoflurane (3.5%,
1 liter/min). A midline incision was made in the scalp to
expose the skull. A hole was drilled into the skull over the
right lateral ventricle at the following coordinates: AP =
-0.5 mm; ML = -1.0 mm. With a 10-μl Hamilton syringe
with a blunt 28-gauge needle, veh or LPS was injected at
the following coordinates: AP = -0.5 mm; ML = -1.0 mm;
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DV= -1.8 mm. The Quintessential Stereotaxic Injector
(Stoelting Co, Wood Dale, IL, USA) was used to inject
2 μl at a rate of 0.5 μl per min. After injection, the needle
was left in place for 2 min before being slowly withdrawn.
The incision was closed using staples, and the animal was
kept on a heat pad until return of normal activity, at which
time the mouse was returned to its home cage. Serum and
brain tissues were harvested at 6 hr after treatment. Intra-
peritoneal (IP) administrations of LPS (5 mg/kg) or veh
were done as previously described [27]. Serum and brain
tissues were harvested at 1, 6, and 24 hr after treatment.
Tissue collection and processing
Mice were injected with an overdose of sodium pentobar-
bital (Pentasol powder; Vibrac Animal Health, Ft Worth,
TX, USA: cat. no. NDC-051311-103-25). Blood was col-
lected by cardiac puncture, prior to transcardiac perfusion
with ice-cold phosphate buffered saline (PBS) for 5 min.
The mice were then decapitated. The brain was dissected
on ice, snap-frozen in liquid nitrogen, and stored at 80°C
until time of use. Brain tissue (cortex or hippocampus)
was homogenized using high shear homogenizer, in a 1:10
(w/v) of ice-cold freshly prepared lysis buffer consisting of
PBS containing 1 μg/ml Leupeptin, 1 mM PMSF, and
1 mM EDTA. The tissue homogenate was centrifuged at
14,000 × g for 20 min at 4°C in a microcentrifuge, and su-
pernatants were collected and stored at -80°C until use.
Microglia and mixed glia cultures
Microglia cultures were prepared as previously described
[32]. Briefly, mixed glial cultures (approximately 95% as-
trocytes, approximately 5% microglia) were prepared
from the cerebral cortices of 1 to 3 day old mice. The
tissue was trypsinized, and the cells were resuspended in
glia complete medium (α-minimum essential medium
(α-MEM; Mediatech, Manassas, VA, USA) supplemented
with 10% fetal bovine serum (FBS) (US Characterized
FBS; Hyclone; Cat no. SH30071.03), 100 IU/ml penicil-
lin, 100 μg/ml streptomycin, and 2 mM L-Glutamine).
After 10 to 14 days in culture, microglia were isolated
from the mixed glial cultures by the shake-off procedure
[33]. Loosely adherent microglia were shaken off at
250 rpm for 2 hr at 37°C. The cell-containing medium
was centrifuged at 180 × g for 3 min, and the cells were
seeded onto 48-well plate at a density of 2 × 104. Alter-
natively, the mixed glia cultures were trypsinized and
seeded onto a 48-well plate at a density of 2 × 104. Cells
were maintained for 24 hr in glia complete medium. LPS
(3 ng/ml) or saline veh was then added directly to the
glia complete medium for 30 min, after which the LPS- or
veh-containing media was removed, the cells were washed
once in glia complete medium, and then maintained for
24 hr in glia complete medium. Aliquots (5 μl) of the con-
ditioned medium from the primary microglia and the
mixed glia cultures were harvested at different times for
cytokine measurements.
Peritoneal macrophages and cortical microglia isolation
for gene expression
Peritoneal macrophages were isolated following standard
procedures as previously described [34,35]. Briefly, the
mice were anesthetized, and 10 ml of PBS was injected
into and recollected from the peritoneal cavity. The mice
were then transcardiac-perfused with ice-cold PBS. The
brain was harvested and the cortex was collected for
microglia isolation. Microglia were isolated from the
brain using a Percoll gradient following standard proce-
dures as previously described [36]. Briefly, the brain tis-
sue was homogenized in 6.5 ml of ice-cold PBS using a
dounce homogenizer. The brain homogenate was added
to 3 ml of 100% isotonic Percoll (ISP) in a 15-ml conical
tube and mixed by inversion. A 2-ml layer of 50% ISP
and 2-ml layer of 70% ISP were layered under the 100%
ISP/brain homogenate (30% ISP in solution). The 15-ml
conical tube containing the Percoll gradient was centrifuged
at 500 × g for 20 min at room temperature. Microglia were
collected at the 70% to 50% ISP interface. Peritoneal macro-
phages and cortical microglia were washed once in PBS be-
fore RNA extraction. RNA was isolated using an RNeasy
kit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s protocols. RNA quantity and quality were deter-
mined using A260/A280 readings by NanoDrop (Thermo
Scientific). Reverse transcription (RT) was done following
the manufacturer's protocol using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Life Tech-
nologies, Grand Island, NY, USA). Controls included no
template and no RT conditions. Real-time PCR was per-
formed using the TaqMan Gene Expression Assay kit
(Applied Biosystems, Life Technologies, Grand Island, NY,
USA) according to the manufacturer's instructions on a
ViiA™ 7 Real-Time PCR System (Applied Biosystems, Life
Technologies, Grand Island, NY, USA). The following
TaqMan probes (Applied Biosystems) were used: CCR2
(Mm00438270-m1); CX3CR1 (Mm02620111_s1); MAPK14
(Mm00442497_m1); 18S (Hs99999901_s1). Relative gene
expression was calculated by the 2 - ΔΔCT method.
Cytokine measurements
IL-1ra levels were measured with an R&D Systems DuoSet
ELISA kit (R&D Systems, Minneapolis, MN, USA: cat. no.
DY480) according to the manufacturer’s specifications. All
other cytokine levels were measured as previously described
[27,37] using Meso Scale Discovery (MSD: Rockville, MD,
USA) custom multiplex high-sensitivity ELISA kits ac-
cording to the manufacturer’s instructions. Tissue cyto-
kine levels were normalized to the total amount of protein
in the sample, as determined by BCA Protein Assay
(Pierce, Rockford, IL, USA).
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Statistics
Statistical analysis was conducted using GraphPad prism
software V.6 (GraphPad Software, La Jolla, CA, USA:
http://www.graphpad.com). Comparisons between LPS-
stimulated WT and p38αΔLysM-Cre KO mice were made
by unpaired t-test. Comparisons were not made between
naïve, or vehicle-injected mice as the cytokine levels
were found to be consistently below or at the limit of
detection. Statistical significance was defined as P <0.05.
Values are expressed as mean ± SEM.
Results
The in vitro levels of TNFα in response to lipopolysaccharide
are reduced in the p38αΔLysM-Cre knockout mice
We have previously demonstrated using primary micro-
glia cultures that the induction of TNFα in response to
TLR activation is governed by p38α, such that loss or in-
hibition of p38α results in less TNFα in response to
stimuli [27,32]. However, in vivo, we recently found that
the role of p38α in regulating proinflammatory cytokine
responses, including TNFα, is more complicated than
that predicted from our in vitro results. Specifically,
using a LysM-Cre mouse line to selectively knock out
p38α in cells of the myeloid lineage (p38αΔLysM-Cre KO
mice), we found that the acute (6 hr post-injury) proin-
flammatory cytokine response to a diffuse TBI was en-
hanced in the KO mice compared to WT controls, even
though the chronic cytokine levels were reduced in the
p38αΔLysM-Cre KO mice [28]. These in vivo results sug-
gest that p38α can both stimulate and unexpectedly limit
the CNS proinflammatory cytokine response to injury.
However, the mechanism by which p38α may suppress
the acute CNS proinflammatory cytokine response has
yet to be identified.
To begin to elucidate the mechanism by which p38α
could limit the CNS proinflammatory cytokine response,
we returned to our in vitro primary microglia and mixed
glia assays. Our prior work measured the levels of TNFα
that accumulated in the conditioned media with LPS
present in cultures for a minimum of 18 hr. However,
our in vivo TBI results showed that the acute cytokine
response was higher in the p38αΔLysM-Cre KO mice at
6 hr post-injury, but lower by 7 d post-injury [28]. We
hypothesized that p38α may have different effects tem-
porally in the TNFα response (that is, an acute spike
during the first 6 hr in TNFα levels), which we did not
detect in our prior in vitro assays when LPS was con-
tinuously present, and TNFα was allowed to accumulate
in the well for 18 hr. To test this idea, we treated primary
microglia cultures with LPS for only 30 min, then re-
moved the media, washed the cells once, and then added
fresh medium (without LPS). The purpose of removing
the LPS was to eliminate the chronic TLR4 pathway acti-
vation, which we know in microglia is partially dependent
on p38α [27,32]; in this way we could look more select-
ively at feedback mechanism. We sampled 5 μl of
microglia-conditioned media every 2 hr for the first 8 hr
and at 24 hr after LPS stimulation, and measured TNFα
levels. As shown in Figure 1A, at all time points from 2 to
Figure 1 Microglia and mixed glia cultures from p38αΔLysM-Cre
knockout (KO) are less responsive to lipopolysaccharide (LPS).
Wild-type (WT) (white) or p38αΔLysM-Cre KO (black) primary microglia
(A) and mixed glia (B) were stimulated with LPS for 30 min, cells washed,
and then conditioned media was harvested at select time points for
TNFα Meso Scale Discovery (MSD) assays. The data are representative
of three independent experiments. (*P <0.05; ***P <0.0005).
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24 hr, significantly lower TNFα levels were found in the
p38αΔLysM-Cre KO primary microglia compared to the WT
microglia (***P <0.0005), in agreement with our prior
work [27,32].
The primary microglia assays we use are enriched such
that approximately 95% of the cells are microglia. There-
fore, we postulated that an interaction between astro-
cytes and microglia might account for the in vivo
findings, which would not be observed when microglia
were in isolation from astrocytes. To test this potential
mechanism, we measured the production of TNFα in
mixed glia cultures (astrocytes and microglia) treated
with LPS and found that the levels of TNFα were also
significantly lower in the mixed glia from p38αΔLysM-Cre
KO mice compared to the WT mice (Figure 1B). Thus,
primary microglia or mixed glia cultures derived from
p38αΔLysM-Cre KO mice show significantly less TNFα in-
duction in response to LPS stimulation compared to
WT mice at all time points examined from 2 to 24 hr.
Overall, these results do not explain the in vivo observa-
tion of enhanced acute proinflammatory cytokine re-
sponse following TBI in p38αΔLysM-Cre KO mice.
In vivo, p38α is efficiently deleted in acutely isolated
adult peritoneal macrophages, but not in acutely isolated
microglia from p38αΔLysM-Cre knockout mice
Recently, Butovsky et al. (2014) reported the gene expres-
sion signature of acutely isolated lymphocytes (B and T
cells), myeloid cells (that is, dendritic cells, macrophages,
and microglia), as well as astrocytes, oligodendrocytes, and
neurons [38]. Microglia were found to express 10 times
higher levels of p38α (MAPK14) compared to astrocytes, ol-
igodendrocytes, or neurons. In addition, microglia expressed
two- to threefold more p38α than other tissue macrophage
populations [38]. We previously reported [27,32] that
p38α is efficiently depleted in primary microglia from
p38αΔLysM-Cre KO mice. However, the LysM-Cre mouse
line may not have equal efficiency at knocking down
p38α in vivo in all myeloid cell populations. For ex-
ample, the recombination efficacy of the LysM-Cre in
microglia in the adult brain has been shown to be be-
tween 20 and 45%, depending on the brain region
and the method used to assess the recombination
[39]. Since both the relative expression of p38α and
the efficiency of the LysM-Cre promoter can vary in
different myeloid cell populations, we measured the
level of p38α suppression in acutely isolated periton-
eal macrophages and cortical microglia from WT and
p38αΔLysM-Cre KO mice.
Using CCR2 and CX3CR1 as markers for macrophages
and microglia, respectively, we found high levels of
CCR2 in the peritoneal macrophages, and high levels of
CX3CR1 in the microglia cell fraction (Figure 2), con-
sistent with previous studies [40]. The gene expression
of CCR2 and CX3CR1 indicated that our isolation re-
sulted in enrichment of the target cell populations. In
the WT mice, we confirmed that expression of p38α was
higher in the microglia fraction compared to the macro-
phage population (Figure 2), as previously reported [38].
Interestingly, in the p38αΔLysM-Cre KO mice, macro-
phages but not microglia were found to have efficient
deletion of p38α (Figure 2). It should be noted that
CCR2 and CX3CR1 expression alone does not indicate
whether cells other than macrophages or microglia are
present in our cell fractions; therefore these results may
underestimate the percentage of microglia that may be
p38α deficient.
These findings would appear to be in disagreement
with our previous reports that p38α is efficiently de-
pleted in primary microglia from p38αΔLysM-Cre KO mice
[27,32]. One potential explanation for the discrepancy is
the culture conditions, as primary microglia are acti-
vated by removal from the CNS tissue environment. The
in vitro activation associated with the primary culture
could be sufficient to increase the expression of LysM,
and the 10 to 14 d of culture would be enough time for
the Cre/loxP recombination to result in a loss of p38α.
Therefore, microglia in culture appear to be more simi-
lar to peritoneal macrophages than to acutely isolated
microglia from adult mice in terms of efficiency of p38α
knockdown.
The proinflammatory cytokine response to
intracerebroventricular (ICV) injection of LPS is not
suppressed in the p38αΔLysM-Cre KO mice
We next postulated that the difference in the acute pro-
inflammatory cytokine response between our in vivo dif-
fuse TBI model and our in vitro LPS model could be the
result of different stressor stimuli. To test this idea, we
induced a sterile inflammatory response in the CNS by
the injection of 25 ng of LPS into the right lateral ventricle
of WT mice and p38αΔLysM-Cre KO mice, thus mirroring
our in vitro LPS assays. Mice were euthanized at 6 hr
post-injection, which was determined by a preliminary ex-
periment (data not shown) as the peak of the IL-1β re-
sponse in the ipsilateral hippocampus following ICV LPS.
Figure 3A shows that levels of three proinflammatory cy-
tokines (IL-1β, IL-6, and TNFα) were increased in the
hippocampus at 6 hr after ICV LPS administration. IL-1β
and TNFα showed no difference between the LPS-
stimulated WT and p38αΔLysM-Cre KO mice. The only dif-
ference between LPS-stimulated WT and p38αΔLysM-Cre
KO mice in CNS responses was a significantly higher up-
regulation of IL-6 (t(14) =2.246 p =0.014) in the cortex, as
well as in the serum of p38αΔLysM-Cre KO mice compared
to WT mice (Figure 3B: (t(14) =3.635 p =0.0027)). We rep-
licated this experiment twice with 100 ng and 1 μg of
LPS and found no difference in IL-1β levels between
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p38αΔLysM-Cre KO mice compared to WT mice at 6 hr
post-injection (data not shown), indicating that the LPS
dose was not a critical variable. We previously found that
IL-1β, IL-6 and TNFα were increased both at the protein
and mRNA level in the cortex following a diffuse TBI in
p38αΔLysM-Cre KO mice [28]. Therefore, the ICV LPS
model more closely resembled our in vivo diffuse TBI
model, than our in vitro LPS model. However, the ICV
LPS model did not mirror the overproduction of IL-1β
and TNFα seen in the in vivo diffuse TBI model. Never-
theless, the ICV LPS model did not show a reduced proin-
flammatory cytokine response in the p38αΔLysM-Cre KO
mice, as seen in the in vitro LPS model. A difference in
the stressor stimuli is thus not able to explain the acutely
elevated levels of proinflammatory cytokines in the CNS
following diffuse TBI in p38αΔLysM-Cre KO mice [28].
As microglia in the p38αΔLysM-Cre KO mice are not p38α
deficient in vivo, the overproduction of IL-6 in re-
sponse to ICV LPS may come from systemic cells, or cir-
culating factors.
The CNS proinflammatory cytokine response to systemic
lipopolysaccharide is enhanced, while the systemic
proinflammatory response is suppressed in the
p38αΔLysM-Cre knockout mice
To test the hypothesis that an altered systemic inflam-
matory response may account for the increased proin-
flammatory cytokine response in the CNS following
diffuse TBI in p38αΔLysM-Cre KO mice, we used an intra-
peritoneal (IP) LPS model. WT and p38αΔLysM-Cre KO
mice were injected IP with 5 mg/kg LPS (3 × 106 EU/
mg). Additionally, to further explore differences in the
temporal patterning of the proinflammatory cytokine re-
sponse in the WT and p38αΔLysM-Cre KO mice, serum and
cortical tissue were harvested at different time points after
LPS insult. In agreement with previous studies [29], we
found a significantly lower serum cytokine response to
LPS in the p38αΔLysM-Cre KO mice compared to WT
mice (Figure 4A). At 1 hr post-injection, the p38αΔLysM-
Cre KO mice had significantly less IL-6 (t(8) =5.062 P =
0.001) and TNFα (t(8) =2.479 P =0.0382) compared to the
WT mice. In agreement with our previous study in the
diffuse TBI model [28], we found a significantly elevated
peak LPS-induced CNS cytokine response in the
p38αΔLysM-Cre KO mice compared to the WT mice
(Figure 4B). At 6 hr post-injection, levels of IL-1β (t(16) =
3.823 P = 0.0015), IL-6 (t(7) = 3.526 P = 0.0097), and TNFα
(t(16) = 2.328 P = 0.0333) were significantly higher in the
p38αΔLysM-Cre KO compared to the WT mice. In an inde-
pendent experiment, we used a lower dose of LPS (1 mg/
kg) and still found a significant increase in IL-1β and IL-6
in the CNS of p38αΔLysM-Cre KO mice compared to the
WT mice at 6 hr post injection (data not shown). There-
fore, the results of the IP LPS model support the hypoth-
esis that systemic cells, or circulating factors dependent
on p38α, are important for limiting the proinflammatory
cytokine response in the CNS.
The p38αΔLysM-Cre knockout mice fail to produce IL-10 in
response to systemic lipopolysaccharide
It has been previously reported that p38α is involved
in the production of two anti-inflammatory cytokines,
IL-1ra [41] and IL-10 [42,43]. Therefore, we hypothesized
that loss of a paracrine anti-inflammatory response might
be responsible for the increased CNS proinflammatory cy-
tokines in the p38αΔLysM-Cre KO mice. To test this, we
measured serum and cortex levels of IL-1ra and IL-10 after
systemic LPS administration to WT and p38αΔLysM-Cre KO
mice. We found no significant difference in the levels of
IL-1ra in the serum between WT and p38αΔLysM-Cre KO
Figure 2 Isolation of peritoneal macrophages (φ) and microglia (μglia) from adult mice shows enrichment of CCR2 and CX3CR1 cell
populations, and loss of p38α in the isolated macrophages but not in the microglia fraction. RNA was extracted from peritoneal
macrophages or microglia isolated from cortical tissue using a discontinuous Percoll gradient. qRT-PCR using TaqMAN Gene Expression Assays
was used to determine CCR2, CX3CR1, and p38α (MAPK14) expression in the isolated cell populations. Data are presented as fold change of
wild-type (WT) macrophages. The data are representative of two independent experiments.
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mice at any time point measured (Figure 5A). In contrast,
we found that the levels of IL-10 in the serum were mark-
edly suppressed in the p38αΔLysM-Cre KO mice compared
to the WT mice following LPS stimulation (Figure 5A). At
1 hr, a highly significant (t(8) = 6.033 P = 0.0003) suppres-
sion of the IL-10 response was seen in the p38α KO mice.
The levels of IL-10 in the serum of the p38αΔLysM-Cre KO
mice remained suppressed at the 6 hr (t(8) = 4.996 P =
0.0011) and 24 hr (t(8) = 3.727 P = 0.0058) time points
compared to the WT mice. In the cortex, there was also
no significant difference in the levels of IL-1ra (Figure 5B)
between p38αΔLysM-Cre KO and WT mice. At 6 hr after
LPS, there were lower IL-10 levels in the cortex of
p38αΔLysM-Cre KO mice compared to the WT mice, but
the decrease did not reach significance (Figure 5B). Thus, a
loss of the systemic IL-10 response in the p38αΔLysM-Cre
KO could be the mechanism by which proinflammatory
cytokine response in the CNS becomes exaggerated.
Discussion
The goal of this project was to explore the potential
mechanism by which p38α could suppress the acute pro-
inflammatory cytokine response in the CNS. Our prior
work, using in vitro assays, demonstrated that p38α is
critical for the production of IL-1β and TNFα from acti-
vated microglia [27,32]. We also previously showed,
using a small molecule p38α inhibitor, that suppression
of the p38α signal transduction pathway limits the IL-1β
response in the CNS to systemic LPS [17,27,44]. More-
over, we found that p38β MAPK is not involved in the
CNS cytokine production, or in neurotoxicity induced
by LPS inflammatory insult or multiple toxic insults
[45,46]. Despite this strong precedent for p38α, we re-
cently found that in a diffuse TBI model the acute proin-
flammatory cytokine response in the CNS was higher in
the p38αΔLysM-Cre KO mice [28]. Therefore, we sought
to determine the mechanism by which p38α could limit
the acute proinflammatory response, as this could be
critical in the use of p38α as a therapeutic target to treat
diseases of the CNS that have inflammation as one com-
ponent of the pathophysiology.
Collectively, our results suggest that p38α has a critical
role in limiting the acute cytokine storm, and the spread
of the systemic innate immune response to the CNS, by
regulating the production of the anti-inflammatory cyto-
kine IL-10. A peripheral injection of LPS into the periton-
eal cavity initiates a systemic innate immune response.
There remains a debate of how the peripheral inflamma-
tion leads to a neuroinflammatory response. However,
acute phase proteins (that is, prostaglandin E2), cytokines
(that is, IL-1β) and LPS itself have been suggested to be
involved in the mechanism by which a peripheral LPS
stimulation induces neuroinflammation [47-51]. In agree-
ment with previous studies [29], we found that levels of
the proinflammatory cytokines IL-1β, IL-6, and TNFα
were all decreased in the serum of mice where macro-
phages were deficient in p38α. Despite the decrease in the
proinflammatory cytokine response in the serum, the peak
of the proinflammatory response in the CNS was signifi-
cantly higher in the p38αΔLysM-Cre KO mice. Our data are
consistent with a model (Figure 6) whereby systemic LPS
induces an acute phase response, including upregulation of
both pro- and anti-inflammatory cytokines. In WT mice,
the balance of the pro- and anti-inflammatory cytokine
Figure 3 p38αΔLysM-Cre knockout (KO) mice show no
suppression of the proinflammatory cytokine response to
intracerebroventricular (ICV) injection of lipopolysaccharide
(LPS). At 6 hr post-ICV injection, levels of cytokines were measured
in the ipsilateral hippocampus (A) and serum (B) of wild-type (WT)
mice (white) or p38αΔLysM-Cre KO mice administered saline (vehicle
(veh): gray) or 25 ng LPS (black). (n = 4 per veh group (WT = 2,
KO = 2); n = 8 per LPS group) (*P <0.05).
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Figure 4 Levels of pro-inflammatory cytokines in the serum and cortex of mice following systemic lipopolysaccharide (LPS) stimulation.
Wild-type (WT) mice (white) or p38αΔLysM-Cre knockout (KO) mice (black) were injected intraperitoneally (IP) with 5 mg/kg LPS. The cytokine response
in the serum was significantly reduced in the p38αΔLysM-Cre KO mice (A), while the response in the CNS was increased in the p38αΔLysM-Cre KO mice
compared to the WT mice (B) (n =5 to 8 per group) (*P <0.05; **P< 0.01; ***P <0.001).
Figure 5 Levels of anti-inflammatory cytokines in the serum and cortex of mice following systemic lipopolysaccharide (LPS) stimulation.
Wild-type (WT) mice (white) or p38αΔLysM-Cre knockout (KO) mice (black) were injected intraperitoneally (IP) with 5 mg/kg LPS. No significant differences
in IL-1ra levels in serum (A) or CNS (B) were detected between WT and p38αΔLysM-Cre KO mice. Levels of IL-10 in the serum were significantly reduced
in the p38αΔLysM-Cre KO mice (A), and there was a trend for reduced levels of IL-10 in the CNS (B) although the data did not reach statistical significance
(n =5 to 8 per group) (**P <0.01; ***P <0.001).
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response, along with other acute phase mechanisms, leads
to an increase in cytokines in the CNS (Figure 6A). How-
ever, if circulating IL-10 levels are not elevated to counter-
balance the increased systemic proinflammatory responses,
the spread of the inflammatory response from the periph-
ery to the CNS is exaggerated. This model is also consist-
ent with data from IL-10 deficient mice, in a large number
of in vivo inflammatory models, which collectively suggest
that no other anti-inflammatory cytokine can compensate
for the loss of IL-10, because without IL-10, there will
be aberrant proinflammatory cytokine overproduction
(for review see: [52]). Our results reported here dem-
onstrate that p38α is required by myeloid cells to produce
IL-10 in response to systemic LPS, and without an effective
IL-10 response - a defect seen in the p38αΔLysM-Cre KO
mouse - neuroinflammation can be exaggerated (Figure 6B).
The systemic balance between pro- and anti-inflammatory
factors can influence the proinflammatory cytokine response
in the CNS. For example, relevant to the current study,
IL-10 is able to block proinflammatory cytokine upregula-
tion in the CNS in response to ICV or IP LPS administra-
tion [53,54] and to spinal cord injury [55]. Moreover, IP
LPS in IL-10 KO mice results in a significantly exagger-
ated TNFα, IL-1β and IL-6 response in the plasma and in
the CNS compared to WT mice [56], following a similar
pattern to our results. Both microglia and astrocytes ex-
press the IL-10 receptor; however, in vitro IL-10 was
found to have a suppressive effect only on astrocytes and
not microglia [57]. The effect of IL-10 on microglia was
found to be indirect through the astrocyte production of
TGFβ [57]. We do not know if this mechanism would also
be true in our model, but understanding the crosstalk be-
tween microglia and astrocytes in regulating the balance
between pro- and anti-inflammatory factors is an import-
ant future direction.
The broad anti-inflammatory properties of IL-10 are a
result of IL-10’s ability to inhibit innate function of mac-
rophages, neutrophils, and dendritic cells including their
production of proinflammatory cytokines [52,58]. The
present study confirmed previous observations [43,59]
that macrophages require p38α for the production of IL-10,
which suggests that the induction of this anti-inflammatory
cytokine may limit the CNS inflammatory response to LPS.
This finding is in agreement with the role of mitogen-and-
stress-activated kinases 1 and 2 (MSK1/2) in the produc-
tion of IL-10 [42,43]. MSK1/2 is activated by p38 and
Erk1/2 [60]. Microglia and macrophages deficient in p38α
have been shown to have decreased levels of the activated
phospho-MSK1/2 [27,42,43]. Critically, MSK1/2 double
KO mice are found to have elevated proinflammatory
cytokine responses to LPS, which is IL-10 dependent, as
illustrated elegantly by the use of an MSK1/2 / IL-10 triple
KO mouse [42]. In addition to the MSK1/2 pathway, p38α
can also regulate IL-10 expression in macrophages via the
direct downstream target of p38α, the MAPK-activated
protein kinase 2 [61]. Defining why Erk1/2 is not able
to compensate for the loss of p38α will require future
studies to understand potential crosstalk between p38α
and Erk1/2 in regulating IL-10 levels following in vivo LPS
stimulation.
Conclusions
We and others have previously reported using small mol-
ecule inhibitors that suppression of p38α can reduce neu-
roinflammation in vivo [16,17,19,23,27]. In the current
study, we found that the peak proinflammatory cytokine
response to systemic LPS in vivo is significantly greater in
the CNS of p38αΔLysM-Cre KO mice compared to the WT
mice, replicating the result found in a diffuse TBI model
[28]. We also found that after systemic stimulation of the
Figure 6 Proposed model for p38α in myeloid cell cytokine response to systemic lipopolysaccharide (LPS). (A) In wild-type (WT) mice,
myeloid cells respond to systemic LPS by producing an acute phase response, including the production of proinflammatory cytokines, as well as
the anti-inflammatory cytokine IL-10. The systemic response spreads to the brain where microglia produce cytokines locally in the CNS. (B) In the
p38αΔLysM-Cre knockout (KO) mice, the systemic acute phase response is suppressed such that there is less proinflammatory cytokine production
in the blood. However, there is also a loss of the negative feedback provided by the anti-inflammatory IL-10, which we propose leads to an
exaggerated acute proinflammatory cytokine response in the CNS.
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innate immune system with LPS, p38α was necessary for a
stimulus-induced increase in serum levels of the anti-
inflammatory cytokine IL-10. Therefore, p38α appears to
be a fulcrum in balancing the systemic innate immune re-
sponse, by regulating levels of pro- and anti-inflammatory
cytokines. While p38α appears to be a promising thera-
peutic target, our work here highlights the complexity of
such efforts. The observations that p38α may balance the
inflammatory response by acutely attenuating the early
proinflammatory cytokine surge, while perpetuating the
chronic microglia activation response raise the importance
of considerations of an optimal therapeutic window for
the efficacy of p38α inhibitors. Our findings that p38α-
dependent systemic inflammatory responses affect the
CNS inflammatory responses also suggest that measure-
ment of systemic IL-10 and TNFα levels in serum or
plasma might be a useful tool for monitoring the anti- and
pro-inflammatory cytokine balance during the course of
treatment of CNS disorders.
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